CTMX FY 2019 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M-3.4% YoY

Gross Profit

$57M100.0% margin

Operating Income

-$111M-192.9% margin

Net Income

-$102M-177.8% margin

EPS (Diluted)

$-2.26

Cash Flow

Operating Cash Flow

-$140M

Free Cash Flow

-$144M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$341M

Total Liabilities

$290M

Stockholders' Equity

$51M

Cash & Equivalents

$188M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$60M	-3.4%
Gross Profit	$57M	$60M	-3.4%
Operating Income	-$111M	-$78M	-42.4%
Net Income	-$102M	-$85M	-20.8%